Atherosclerosis:动脉粥样程度并不影响生物标志物与心血管疾病的相关性

2016-10-31 MedSci MedSci原创

背景:已经分别研究了心血管疾病(CVD)与生物标志物和动脉粥样硬化成像的相关性,但是动脉粥样硬化程度是否影响生物标志物与心血管疾病的相关性的研究较少。在这项研究中,研究者评估一级预防队列中,颈动脉内膜中层厚度(CIMT)评估的动脉粥样硬化是否影响与冠心病(CHD)和心血管疾病(CVD)相关的生物标志物的相关性。方法:在ARIC研究中根据动脉粥样硬化的程度(cIMT),将8127名(第四次访问,19

背景:已经分别研究了心血管疾病(CVD)与生物标志物和动脉粥样硬化成像的相关性,但是动脉粥样硬化程度是否影响生物标志物与心血管疾病的相关性的研究较少。在这项研究中,研究者评估一级预防队列中,颈动脉内膜中层厚度(CIMT)评估的动脉粥样硬化是否影响与冠心病(CHD)和心血管疾病(CVD)相关的生物标志物的相关性。

方法:在ARIC研究中根据动脉粥样硬化的程度(cIMT),将8127名(第四次访问,1996-1998)进行分层:最小的,中等的,最大的。检测每个受试者的C-反应蛋白、脂蛋白磷脂酶A2、肌钙蛋白T、N末端脑钠肽前体、脂蛋白(a)、胱抑素C、尿白蛋白/肌酐比值测定。应用RR值确定动脉粥样硬化各分层中,生物标志物和冠心病,卒中和心血管疾病的相关性。

结果:虽然每个生物标志物与相关事件的风险显著相关,研究者发现不同程度的动脉粥样硬化,生物标志物与与冠心病,卒中和心血管疾病相关的程度没有显著的差异。

结论:这些研究结果表明,动脉粥样硬化程度并没有显着影响生物标志物与心血管疾病之间的相关性。

原始出处:

Agarwala A, Virani S, et al. Biomarkers and degree of atherosclerosis are independently associated with incident atherosclerotic cardiovascular disease in a primary prevention cohort: The ARIC study. Atherosclerosis. 2016 Oct


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1947315, encodeId=bf06194e3156c, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 14 05:00:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840932, encodeId=0b981840932b1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Mar 14 05:00:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837205, encodeId=5133183e205b8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 13 05:00:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364133, encodeId=db911364133c9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498079, encodeId=354914980e97f, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560574, encodeId=64a115605e443, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566583, encodeId=3a80156658352, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1947315, encodeId=bf06194e3156c, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 14 05:00:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840932, encodeId=0b981840932b1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Mar 14 05:00:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837205, encodeId=5133183e205b8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 13 05:00:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364133, encodeId=db911364133c9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498079, encodeId=354914980e97f, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560574, encodeId=64a115605e443, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566583, encodeId=3a80156658352, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1947315, encodeId=bf06194e3156c, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 14 05:00:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840932, encodeId=0b981840932b1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Mar 14 05:00:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837205, encodeId=5133183e205b8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 13 05:00:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364133, encodeId=db911364133c9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498079, encodeId=354914980e97f, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560574, encodeId=64a115605e443, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566583, encodeId=3a80156658352, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1947315, encodeId=bf06194e3156c, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 14 05:00:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840932, encodeId=0b981840932b1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Mar 14 05:00:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837205, encodeId=5133183e205b8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 13 05:00:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364133, encodeId=db911364133c9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498079, encodeId=354914980e97f, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560574, encodeId=64a115605e443, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566583, encodeId=3a80156658352, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=)]
    2016-11-02 lsndxfj
  5. [GetPortalCommentsPageByObjectIdResponse(id=1947315, encodeId=bf06194e3156c, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 14 05:00:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840932, encodeId=0b981840932b1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Mar 14 05:00:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837205, encodeId=5133183e205b8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 13 05:00:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364133, encodeId=db911364133c9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498079, encodeId=354914980e97f, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560574, encodeId=64a115605e443, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566583, encodeId=3a80156658352, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1947315, encodeId=bf06194e3156c, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 14 05:00:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840932, encodeId=0b981840932b1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Mar 14 05:00:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837205, encodeId=5133183e205b8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 13 05:00:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364133, encodeId=db911364133c9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498079, encodeId=354914980e97f, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560574, encodeId=64a115605e443, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566583, encodeId=3a80156658352, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1947315, encodeId=bf06194e3156c, content=<a href='/topic/show?id=d6bc160453b' target=_blank style='color:#2F92EE;'>#Sclerosis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16045, encryptionId=d6bc160453b, topicName=Sclerosis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=33b92500139, createdName=12498b37m72暂无昵称, createdTime=Mon Aug 14 05:00:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1840932, encodeId=0b981840932b1, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Tue Mar 14 05:00:00 CST 2017, time=2017-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837205, encodeId=5133183e205b8, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 13 05:00:00 CST 2017, time=2017-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364133, encodeId=db911364133c9, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498079, encodeId=354914980e97f, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1560574, encodeId=64a115605e443, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1566583, encodeId=3a80156658352, content=<a href='/topic/show?id=3c746936567' target=_blank style='color:#2F92EE;'>#生物标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69365, encryptionId=3c746936567, topicName=生物标志)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63db15173977, createdName=zhu_jun9842, createdTime=Wed Nov 02 10:00:00 CST 2016, time=2016-11-02, status=1, ipAttribution=)]

相关资讯

Circulation:家族性高胆固醇血症患者动脉粥样硬化性心血管疾病的长期风险增加

在美国每200个成年人都会受到杂合子家族性高胆固醇血症(FH)的影响,但在美国一般FH人群中动脉粥样硬化性心血管疾病(ASCVD)的结果还没有被描述。因此,研究人员试图评估美国FH型成年人长期冠状动脉心脏疾病(CHD)和总的ASCVD风险。研究人员使用了美国6大流行病学队列研究中的汇总数据,通过从20〜79岁参与者的低密度脂蛋白胆固醇水平进行分层。对于主要分析,低密度脂蛋白胆固醇水平≥190和&l

盘点:2016动脉粥样硬化研究亮点(top10)

动脉粥样硬化(atherosclerosis,AS)是冠心病、脑梗死、外周血管病的主要原因,是动脉壁上沉积一层包括胆固醇结晶在内的粥样物质,使动脉弹性降低、管腔变窄,常导致心肌梗塞、中风等致命疾病发生。胆固醇结晶会引发免疫反应,导致动脉壁出现可致命的炎症。关于2016年动脉粥样硬化相关研究重大成果,小M与您分享。【1】Circulation:动脉粥样硬化血栓形成危险分层及沃拉帕沙的二级预防作用

Circulation:中国-PAR计划——制定我国10年动脉粥样硬化心血管病的预测模型

背景:对个人风险的准确评估对指导和预防动脉粥样硬化性心血管疾病(ASCVD)是很有价值的。然而,常用的预测模型主要是在白人人群中制定的。这个项目的目的是开发和验证中国人群ASCVD的十年风险预测模型。方法: 21320中国受试者中,对两个前瞻性研究统一进行随访作为推导队列形成10年ASCVD风险预测模型。有123 14和838 70名受试者的两个独立的中国队列中进行外部验证。此外,与美国心脏病学会

Nature:抗肿瘤CD47抗体有望阻止动脉粥样硬化

在一项新的研究中,来自美国斯坦福大学医学院的研究人员发现让肿瘤细胞展示在它们表面上的保护它们自己免受免疫系统吞噬的一种信号也在动脉粥样硬化---经常导致心脏病和中风发作---产生过程中发挥着作用。相关研究结果于2016年7月20日在线发表在Nature期刊上,论文标题为“CD47-blocking antibodies restore phagocytosis and prevent athe

葛均波 孔灵芝 陈韵岱 孟宪励——膳食胆固醇究竟要不要控制?

目前从学术界到广大民众普遍关心一个热点话题:膳食胆固醇的摄入究竟要不要进行限制?这个问题正如哈姆雷特的那句“To be or not to be, that is the question.”不同的对象、不同的环境、不同的程度,自然会带来不同的结局。因此从这个意义而言,邀请权威专家讨论正是为了明确其界限,让科学的认知引导广大民众,及时传递对胆固醇的正确认识。问:胆固醇是导致动脉粥样硬化性心脏病

JACC:Canakinumab对动脉粥样硬化患者的血管结构或功能无显著影响

有证据表明,白细胞介素(IL)-1β在动脉粥样硬化及其并发症发病机制中有重要的作用,抑制IL-1β对于血管疾病进展有利。来自英国的研究人员开展了一项研究,这项研究的目的是评估canakinumab vs 安慰剂抑制IL-1β与对动脉结构和功能的影响,由磁共振成像进行测定。患有动脉粥样硬化疾病和2型糖尿病或葡萄糖耐量降低的患者(n=189)随机接受安慰剂(n=94)或canakinumab每月150